Syntrix Pharmaceuticals is a leading biopharmaceutical company based in Auburn, WA, specializing in the development of breakthrough medicines. With a strong focus on immuno-oncology and pain research, Syntrix is dedicated to advancing innovative therapies that have the potential to transform patient outcomes.
Driven by a convergent science strategy, Syntrix's pipeline of hope includes promising candidates such as SX-682, which has shown great potential in enhancing the effectiveness of therapies targeting the RAS RAF MEK ERK signaling pathway in non-small cell lung cancer. Committed to corporate responsibility, Syntrix is at the forefront of developing novel strategies to combat cancer and improve the lives of patients worldwide.
Generated from the website